Fmr LLC Reduces Position in Enanta Pharmaceuticals, Inc. (ENTA)

Fmr LLC decreased its stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 3.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 276,815 shares of the biotechnology company’s stock after selling 10,000 shares during the period. Fmr LLC owned about 1.45% of Enanta Pharmaceuticals worth $9,960,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of ENTA. Wells Fargo & Company MN lifted its stake in Enanta Pharmaceuticals by 82.5% in the 1st quarter. Wells Fargo & Company MN now owns 21,394 shares of the biotechnology company’s stock valued at $660,000 after purchasing an additional 9,674 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Enanta Pharmaceuticals by 2.6% in the 1st quarter. Bank of New York Mellon Corp now owns 199,078 shares of the biotechnology company’s stock valued at $6,132,000 after purchasing an additional 5,022 shares during the last quarter. Swiss National Bank lifted its stake in Enanta Pharmaceuticals by 5.4% in the 1st quarter. Swiss National Bank now owns 23,500 shares of the biotechnology company’s stock valued at $724,000 after purchasing an additional 1,200 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in Enanta Pharmaceuticals by 2.5% in the 1st quarter. Ameriprise Financial Inc. now owns 116,415 shares of the biotechnology company’s stock valued at $3,586,000 after purchasing an additional 2,880 shares during the last quarter. Finally, Parametric Portfolio Associates LLC lifted its stake in Enanta Pharmaceuticals by 20.2% in the 1st quarter. Parametric Portfolio Associates LLC now owns 11,854 shares of the biotechnology company’s stock valued at $365,000 after purchasing an additional 1,989 shares during the last quarter. 66.23% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/10/31/fmr-llc-reduces-position-in-enanta-pharmaceuticals-inc-enta.html.

Several equities analysts recently commented on the stock. J P Morgan Chase & Co reissued an “overweight” rating and issued a $38.00 price objective (up previously from $32.00) on shares of Enanta Pharmaceuticals in a research note on Wednesday, August 9th. Robert W. Baird increased their price objective on shares of Enanta Pharmaceuticals from $27.00 to $36.00 and gave the company a “neutral” rating in a research note on Tuesday, August 8th. BidaskClub raised shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, August 11th. Royal Bank Of Canada reissued a “buy” rating and issued a $54.00 price objective on shares of Enanta Pharmaceuticals in a research note on Friday, October 20th. Finally, Zacks Investment Research raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 10th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $45.25.

Enanta Pharmaceuticals, Inc. (ENTA) opened at 49.57 on Tuesday. Enanta Pharmaceuticals, Inc. has a 1-year low of $22.17 and a 1-year high of $50.39. The stock’s 50 day moving average is $46.54 and its 200 day moving average is $38.34. The company’s market cap is $946.29 million.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.44) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.49) by $0.05. The firm had revenue of $7.51 million during the quarter, compared to analyst estimates of $8.08 million. Enanta Pharmaceuticals had a negative net margin of 51.85% and a negative return on equity of 7.74%. The business’s quarterly revenue was down 46.3% on a year-over-year basis. During the same period in the previous year, the business posted ($0.06) EPS. Equities analysts anticipate that Enanta Pharmaceuticals, Inc. will post $1.16 earnings per share for the current fiscal year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA).

Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

What are top analysts saying about Enanta Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Enanta Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit